Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An update from Genfit SA ( (GNFT) ) is now available.
On February 21, 2025, GENFIT announced the preliminary results of its repurchase offer for 2025 OCEANEs holders, signing agreements with holders representing 95.3% of the outstanding bonds. A general meeting is set for March 10, 2025, to approve amendments and finalize the royalty financing deal, impacting GENFIT’s financial strategy and bondholder relations.
More about Genfit SA
GENFIT is a late-stage biopharmaceutical company focused on rare and life-threatening liver diseases, with a diverse R&D portfolio targeting conditions such as Acute-on-Chronic Liver Failure, cholangiocarcinoma, and more. The company is also involved in diagnostics for liver-related conditions and is listed on Nasdaq and Euronext.
YTD Price Performance: 2.35%
Average Trading Volume: 8,760
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $191M
Learn more about GNFT stock on TipRanks’ Stock Analysis page.
